Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<p>In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine.</p><p>Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In 2020, Southbound trading accounted for 22% of the equity market ADT. </p><p>We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion.</p><p>In this insight, we will highlight inflows into Kuaishou Technology (1024 HK), China Mobile Limited (941 HK),  as well as outflows from Tencent Holdings Limited (700 HK).</p>

In our weekly HK Connect Flow series, we aim to highlight key stocks and sectors which the mainland investors traded via the southbound Hong Kong Connect, as analyzed by our proprietary data engine.Since the opening of Hong Kong Connect scheme in 2014, southbound Chinese money started to play an increasingly important role in the Hong Kong stock market. In 2020, Southbound trading accounted for 22% of the equity market ADT. We split the stocks eligible for the Hong Kong Connect trade into three groups: HSCEI component stocks, stocks with a market capitalization between USD 1 billion and USD 5 billion, and stocks with a market capitalization between USD 500 million and USD 1 billion.In this insight, we will highlight inflows into Kuaishou Technology (1024 HK), China Mobile Limited (941 HK),  as well as outflows from Tencent Holdings Limited (700 HK).

Hong Kong Connect Flows: Kuaishou Inflows

Overseas Chinese Equities, Aequitas Research

Ming Lu

Overseas Chinese Equities

Equity Bottom-Up

<ul class="">
<li>Short video is a promising business in China.</li>
<li>TikTok has a larger user base than Kuaishou.</li>
<li>However, Kuaishou’s time on site grew faster than Tiktok.</li>
<li>Also, Kuaishou’s users are younger than TikTok.</li>
<li>We believe Kuaishou continues to benefit from live video sales.</li>
</ul>
<p>Also see:</p>
<ul>
<li><a href="https://www.smartkarma.com/insights/kuaishou-1024-hk-2q21-direct-response-sales-raised-growth-and-gross-margin" target="_blank" data-smartkarma-citation="insights:56668" rel="noopener">Kuaishou (1024 HK): 2Q21, Direct-Response Sales Raised Growth and Gross Margin</a></li>
<li><a href="https://www.smartkarma.com/insights/kuaishou-1024-hk-opportunity-coming-after-lock-up-expiry" target="_blank" data-smartkarma-citation="insights:55609" rel="noopener">Kuaishou (1024 HK): Opportunity Coming After Lock-Up Expiry</a></li>
</ul>


Short video is a promising business in China.
TikTok has a larger user base than Kuaishou.
However, Kuaishou’s time on site grew faster than Tiktok.
Also, Kuaishou’s users are younger than TikTok.
We believe Kuaishou continues to benefit from live video sales.

Also see:

Kuaishou (1024 HK): 2Q21, Direct-Response Sales Raised Growth and Gross Margin
Kuaishou (1024 HK): Opportunity Coming After Lock-Up Expiry


Kuaishou (1024 HK): Weaker than TikTok? Not Exactly

Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

Equity Analyst

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Several news media outlets reported in September that ByteDance (1439927D CH) has made plans to launch a music streaming app in China later this year. The online music streaming market in China is long dominated by Tencent Music who previously held exclusive music licensing agreements with global music streaming giants Warner Music Group (WMG), Universal Music (UMG) and Sony Music in China. However, TME was ordered to give-up these exclusive music licensing agreements by the country’s market regulator SAMR (state Administration of Market Regulation) and the company announced in August that it has relinquished all of its exclusive music licensing agreements as per the order of the Chinese regulators.TME’s shares are currently trading at US$6.87 per ADR at its all-time low and the shares are down 77.4% compared to its peak of US$30.42 per ADR in mid-March.

TME: ByteDance’s Entry into Music Streaming to Further Threaten TME’s Dominance

Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

Equity Capital Markets

Shanghai MicroPort MedBot Group / Equity Capital Markets

<div><p>MicroPort MedBot (MM), a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO. It is a subsidiary of <a href="https://www.smartkarma.com/entities/microport-scientific-corp" target="_blank" data-smartkarma-citation="entities:4487:1" rel="noopener">Microport Scientific (853 HK)</a> and is backed by Hillhouse and other  mainly domestic investors.</p></div><div><p>MicroPort MedBot (MM) is a surgical robot company which designs, develops and commercializes surgical robots to assist surgeons in performing complex surgical procedures. It is the only company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, as per Frost &amp; Sullivan (F&amp;S).</p></div><div><p>Its flagship products, Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot, have all been admitted to the NMPA’s Green Path. Toumai and Honghu are at or near the registration approval stage, and DFVision has recently received NMPA approval.</p></div><p>We have looked at the company’s background and products in our earlier note, <a href="https://www.smartkarma.com/insights/microport-medbot-pre-ipo-robodoc-pre-revenue-has-a-large-competitor-but-a-large-market-as-well" target="_blank" rel="noopener">MicroPort MedBot Pre-IPO - RoboDoc - pre-revenue, has a large competitor but a large market as well</a>. </p><p>In this note, we will talk about the PHIP updates and look at the performance of its largest competitor.</p>

MicroPort MedBot (MM), a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO. It is a subsidiary of Microport Scientific (853 HK) and is backed by Hillhouse and other  mainly domestic investors.MicroPort MedBot (MM) is a surgical robot company which designs, develops and commercializes surgical robots to assist surgeons in performing complex surgical procedures. It is the only company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, as per Frost &amp; Sullivan (F&amp;S).Its flagship products, Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot, have all been admitted to the NMPA’s Green Path. Toumai and Honghu are at or near the registration approval stage, and DFVision has recently received NMPA approval.We have looked at the company’s background and products in our earlier note, MicroPort MedBot Pre-IPO - RoboDoc - pre-revenue, has a large competitor but a large market as well. In this note, we will talk about the PHIP updates and look at the performance of its largest competitor.

MicroPort MedBot Pre-IPO - RoboDoc - PHIP Updates and a Look at Its Largest Competitor

<p>Hong Kong SFC reported aggregate short position as of Sep 17. The aggregate short value for equities decreased by $2,689m (-3.9%) WoW but increased by $2,234m (+3.5%) over the preceding four weeks.</p><p>Most shorted stocks by aggregate short value of positions are Ping An Insurance (Group) Company Of China, Ltd./2318 HK($3,288m, -11.6% WoW), China Merchants Bank Co., Ltd./3968 HK($2,378m, -13.4% WoW), Zhongsheng Group Holdings Limited/881 HK($1,846m, -5.8% WoW), Anta Sports Products Limited/2020 HK($1,503m, -8.7% WoW), Meituan/3690 HK($1,496m, -15.0% WoW).</p><section class="figure"><figure class="editor-figure mceNonEditable"><img src="https://static-prod.smartkarma.com/images/media/000/232/084/original/Hong_Kong_Market_Short_Position_Value_%28line%29_and_1W_Changes_%28bar%29_%28%24m%292021-09-27+18_20_37.png?1632738370" class="editor-image img-responsive" data-smartkarma-image-id="232084"></figure></section>

Hong Kong SFC reported aggregate short position as of Sep 17. The aggregate short value for equities decreased by $2,689m (-3.9%) WoW but increased by $2,234m (+3.5%) over the preceding four weeks.Most shorted stocks by aggregate short value of positions are Ping An Insurance (Group) Company Of China, Ltd./2318 HK($3,288m, -11.6% WoW), China Merchants Bank Co., Ltd./3968 HK($2,378m, -13.4% WoW), Zhongsheng Group Holdings Limited/881 HK($1,846m, -5.8% WoW), Anta Sports Products Limited/2020 HK($1,503m, -8.7% WoW), Meituan/3690 HK($1,496m, -15.0% WoW).

HK Short Interest: Short Spiked for BeiGene

China

Kuaishou Technology operates as a content community and social platform. The Company helps users create, upload and watch short videos on mobile devices. Kuaishou Technology offers services worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Kuaishou Technology (1024 HK)

Hong Kong Connect Flows: Kuaishou Inflows

We highlight Hong Kong Connect inflows into Kuaishou Technology (1024 HK), China Mobile Limited (941 HK), as well as outflows from Tencent...

Ke Yan, CFA, FRM

Kuaishou (1024 HK): Weaker than TikTok? Not Exactly

Short video is a promising business in China. TikTok owns a larger user base than Kuaishou. However, Kuaishou’s time on site grew faster than...

Ming Lu

TME: ByteDance’s Entry into Music Streaming to Further Threaten TME’s Dominance

ByteDance has made plans to launch a music streaming app in China later this year which is likely to further threaten TME's market dominance as it...

Shifara Samsudeen, ACMA, CGMA

MicroPort MedBot Pre-IPO - RoboDoc - PHIP Updates and a Look at Its Largest Competitor

MicroPort MedBot, a surgical robot company, aims to raise up to US$1bn in its Hong Kong IPO. It is a subsidiary of Microport Scientific (853 HK)...

Sumeet Singh

HK Short Interest: Short Spiked for BeiGene

We highlight in the latest SFC short aggregate report that the top five stocks by WoW increases in short value are Kuaishou, JD Health, BeiGene,...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)